IBRX Trading Analysis - 10/12/2026 10:20 AM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge context for ImmunityBio (IBRX) suggests the following themes that may relate to the technical and sentiment data observed:

• IBRX continued regulatory and commercialization updates on its bladder cancer immunotherapy (Anktiva), with expanded treatment site activations through late 2026.
• Company presented interim survival data at a major oncology conference, drawing renewed speculative interest from retail and options traders.
• No confirmed near-term earnings date in provided data, but fiscal year end is listed as 2025-12-01, with historical volatility elevated at 69.15%.
• Headlines around biotech sector momentum and small-cap speculative flows align with the sharp September–October price rise from $7.64 to $10.81.
• Options market shows heavy directional call conviction, possibly reflecting headline-driven optimism rather than fundamental confirmation.

This news context is separated from the strict data analysis below, which uses only embedded dataset values.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS JSON:

• Trailing EPS is -0.96; company is not profitable (no trailing PE, forward PE null, PEG null).
• Profit margins, revenue growth, ROE, debt-to-equity, and free cash flow are all null in data.
• Market cap is $10,920,550,144.00 with shares outstanding of 1,059,836,000.00.
• Institutional ownership is low at 12.91%; dividend yield 0.00%.
• Beta is -0.17 (inverse market correlation).
• 52-week range: low $1.95, high $12.43; current price near upper half.
• Analyst target mean price and consensus are null; no Wall Street model available.
• Fundamentals show no earnings support, diverging from strong technical and options bullishness.

Current Market Position

From daily history, last close (2026-10-09) is $10.59. Minute bars for 2026-10-12 open at $10.59, range $10.16–$10.62, last printed $10.32 at 09:50. Price pulled back from early session high but held above prior daily close structure.

Intraday momentum: first 5 minute bars on 10-12 show open $10.59 then dip to $10.16 low, recovered to $10.32; volume spike at open (694,966) indicates early distribution.

Technical Analysis

SMA alignment: 5-day ($10.03) > 20-day ($9.06) > 50-day ($8.29); bullish stack, price above all. RSI 69.34 near overbought. MACD histogram +0.11 bullish. Bollinger: middle $9.06, upper $10.58, lower $7.54; price at $10.59 is at/above upper band (expansion). 30-day range high $10.81, low $7.64; price in top 93% of range.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (Delta 40-60 filtered):

Call Volume: $92,735 (90.0%) Put Volume: $10,340 (10.0%) Total: $103,075

Call contracts 656 vs put 77; sentiment tag Bullish. Pure directional positioning shows strong near-term call conviction, aligned with technical uptrend, no divergence in provided data.

Key Price Levels (Observational Only)